MPG.eBooks - Search Results - "Dermatitis, Atopic / Drug Therapy"

Cover Image

1

Clinical review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.) : indication: moderate-to-severe atopic dermatitis (AD)

Published 2018

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

2

Pharmacoeconomic review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.)

Published 2018

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

3

Pharmacoeconomic review report: Dupilumab (Dupixent) (Sanofi-Aventis Canada Inc.)

Published 2018

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

4

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2018

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

5

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

6

Drug class review: Topical calcineurin inhibitors : final report

by Lee, Nancy J.
Published 2008

Oregon Health & Science University

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

7

Clinical review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild to moderate atopic dermatitis in patients 2 years of ag...

Published 2019

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

8

Clinical review report: Dupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.) : indication : indicated for the treatment of patients aged 12 years and old...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

9

Pharmacoeconomic review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two y...

Published 2019

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

10

Pharmacoeconomic review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two y...

Published 2019

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

11

CADTH Canadian Drug Expert Committee recommendation: Crisaborole (Eucrisa -- Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patie...

Published 2019

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”

Cover Image

12

CADTH Canadian Drug Expert Committee recommendation: Crisaborole (Eucrisa -- Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patie...

Published 2019

CADTH

Subjects: “...Dermatitis, Atopic / drug therapy...”